Inhibition of gastric inhibitory polypeptide signaling prevents obesity
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Secretion of gastric inhibitory polypeptide (GIP), a duodenal hormone, is primarily induced by absorption of ingested fat. Here we describe a novel pathway of obesity promotion via GIP. Wild-type mice fed a high-fat diet exhibited both hypersecretion of GIP and extreme visceral and subcutaneous fat deposition with insulin resistance. In contrast, mice lacking the GIP receptor (Gipr(-/-)) fed a high-fat diet were clearly protected from both the obesity and the insulin resistance. Moreover, double-homozygous mice (Gipr(-/-), Lep(ob)/Lep(ob)) generated by crossbreeding Gipr(-/-) and obese ob/ob (Lep(ob)/Lep(ob)) mice gained less weight and had lower adiposity than Lep(ob)/Lep(ob) mice. The Gipr(-/-) mice had a lower respiratory quotient and used fat as the preferred energy substrate, and were thus resistant to obesity. Therefore, GIP directly links overnutrition to obesity and it is a potential target for anti-obesity drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“tirzepatide proved superior in improving glycemic control relative to treatment with semaglutide (1 mg)133, insulin degludec134, insulin glargine135,136, and insulin lispro137; importantly, with preserved efficacy and without compromising safety in subjects at risk for cardiovascular diseases136.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“While GIPR antagonism has been shown to reduce adiposity in preclinical models [64], the clinical data show tirzepatide, a dual GLP-1R/GIPR agonist, produces greater weight loss and glucose lowering than the GLP-1R agonist semaglutide alone [42], particularly at doses which comparably engage the GLP-1R [61].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
In the citing paper
“Initial reports that GIPR null mice [64] are protected from diet-induced obesity have been supported by preclinical studies in rodents and non-human primates that GIPR antagonism induces additive weight loss when combined with GLP-1R agonism [32,67], and human genetics data that loss-of-function GIPR variants associate with reduced adiposity [68].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419 · cited 1×
“Obese Lep ob / Lep ob mice exhibit a marked increase in adipose tissue due to hyperphagia caused by mutation of the leptin gen”
BackgroundSerum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene
Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., & Friedman, J. M. (1995) · Science · doi:10.1126/science.7624777 · Cited by 4,451
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,225
Obesity and the regulation of energy balance
Spiegelman, B. M., & Flier, J. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00240-9 · Cited by 2,398
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Green, H., & Kehinde, O. (1975) · Cell · doi:10.1016/0092-8674(75)90087-2 · Cited by 1,360
Dietary fat intake does affect obesity!
Bray, G. A., & Popkin, B. M. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.6.1157 · Cited by 1,123
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Cited by
Items 801–900 of 972
GIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid
Nauck, M. A., Blüher, M., Meyhöfer, S. M., Heitmann, E., & Görgens, S. W. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2102-2436 · Cited by 3
“Da GIP-Rezeptor knock-out-Mäuse unter Überfütterung weniger zunehmen, gab es Hinweise für eine obesigene Wirkung des GIP-Rezeptor-Agonismus [14].”
BackgroundIncretin-mediated control of cardiac energy metabolism
Chan, J. S. F., Shafaati, T., & Ussher, J. R. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0011 · Cited by 2
Mouse genetics in drug target discovery and validation: no simple answers to complex problems
Russ, A., & Grosse, J. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.10.1379 · Cited by 2
[American Gastroenterological Association. Gastrointestinal hormones and food intake].
Strader, A. D., & Woods, S. C. (2005) · PubMed · Cited by 3
Physiological Responses of Post-Dietary Effects: Lessons from Pre-Clinical and Clinical Studies
Yeung, C., Shi, I. Q., & Sung, H. (2021) · Metabolites · doi:10.3390/metabo11020062 · Cited by 2
“Gastric inhibitory polypeptide (GIP) is an obesity-promoting factor that acts on adipocytes [55,56].”
BackgroundRoles of Gut Hormones in the Regulation of Food Intake and Body Weight
Castagneto‐Gissey, L., Mariolo, J. R. C., & Mingrone, G. (2019) · Endocrinology · doi:10.1007/978-3-319-46933-1_13 · Cited by 3
Mitigating Diabetic Foot Ulcers: The Effect of Diet and Microbiome
Coon, S. D. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106629 · Cited by 2
Ranganath, L. R., & Pinkney, J. H. (2011) · Springer eBooks · doi:10.1007/978-0-387-92271-3_17 · Cited by 2
Nutrients and Peripherally Secreted Molecules in Regulation of Energy Homeostasis
Shetty, G. K., Barb, D., & Mantzoros, C. S. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-985-1_4 · Cited by 3
“Mice lacking the GIP receptor are protected from obesity and insulin resistance ( 113 ), indicating that GIP is implicated in a peripheral, possibly leptin-independent, decrease in EE and fat oxidation, rather than an alteration in energy intake.”
BackgroundGastrointestinal Hormones and Their Regulation of Food Intake
Busetto, L., Rossato, M., & Vettor, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.66106-8 · Cited by 2
Effects of Evening-Only Low-Carbohydrate Meal on Healthy Volunteers
Yaegashi, A., & Suzuki, J. S. (2020) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.66.229 · Cited by 1
Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
Rabenda, M., Słomczyński, A., Zatyka, P., Pawłowska, A., Opala, D., Osuch, D., & Janik, P. E. (2024) · Quality in Sport · doi:10.12775/qs.2024.20.53995 · Cited by 1
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2025) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.05.006 · Cited by 1
Corbalan, J. J., Petronella, B. A., Huang, C., Beasley, J. R., Merritt, J. R., Mugrage, B., & Nickels, J. T. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152360 · Cited by 1
Next-generation anti-obesity drugs: Mechanisms, molecules, and momentum
Mukheja, Y., Kondepudi, K. K., Chopra, K., & Bishnoi, M. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100701 · Cited by 1
Clinical Potential of GIP in Type 2 Diabetes and Obesity
Nauck, M. A., Gribble, F. M., Reimann, F., D’Alessio, D. A., & Campbell, J. E. (2026) · Diabetes Care · doi:10.2337/dci25-0141 · Cited by 3
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
Krogh, L. S. L., Hansen, M. B., Bergmann, N. C., Hansen, C. P., Hartmann, B., Holst, J. J., Knop, F. K., Lund, A., & Gasbjerg, L. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70940 · Cited by 1
“…and exogenous GIP inhibit postprandial bone resorption [6], increase blood flow to the intestines [7], as well as increase heart rate and blood pressure [8], and additionally, exogenous GIP increases blood flow to the adipose tissue [9] and plays a role in adipose tissue signalling in mice [10].”
Self-citationYie, J., Mou, Z., & Liu, X. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag029 · Cited by 2
“…preferentially oxidized fat rather than carbohydrate as an energy source during short-term high-fat feeding, as ref lected by a lower respiratory quotient (RQ), and exhibit increased whole-body energy expenditure during prolonged high-fat feeding, indicated by elevated oxygen consumption [ 34, 35].”
Gao, S., & Borner, T. (2026) · Appetite · doi:10.1016/j.appet.2026.108723 · Cited by 2
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
“Deleting GIPR in mice also leads to less body-weight gain and fat mass accumulation on a high-fat diet, protecting them from diet-induced obesity and insulin resistance compared to wild-type controls [218].”
Smarkusz-Zarzecka, J., Radziszewska, M., Gofron, K. K., & Ostrowska, L. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10098-7 · Cited by 1
Romantsova, T. I. (2009) · Obesity and metabolism · doi:10.14341/2071-8713-5241 · Cited by 1
Zhang, C. Y., Boylan, M. O., Arakawa, H., & Wolfe, M. M. (2019) · Peptides · doi:10.1016/j.peptides.2019.170227 · Cited by 1
Vidal, J. P. (1986) · Memoria digital de Canarias (Universidad de Las Palmas de Gran Canaria) · Cited by 3
Agache, P. G. (2004) · Springer eBooks · doi:10.1007/978-3-662-08585-1_44 · Cited by 1
Orlistat and the Influence on Appetite Signals
Ellrichmann, M. (2011) · Springer eBooks · doi:10.1007/978-0-387-92271-3_86 · Cited by 1
Incretin physiology in health and disease
Meier, J. J., & Nauck, M. A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch11 · Cited by 1
Molecular Biology of Gluco-Incretin Function
Klinger, S., & Thorens, B. (2008) · Springer eBooks · doi:10.1007/978-4-431-75452-7_16 · Cited by 1
Yoder, S. M. (2010) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Gastric inhibitory polypeptide receptor
Hoersch, D., & Schrader, J. (2007) · AfCS-Nature Molecule Pages · doi:10.1038/mp.a001028.01 · Cited by 1
Incretins: new targets for the prevention of diabetes and obesity
Neff, K., & le Roux, C. W. (2013) · Clinical Lipidology · doi:10.2217/clp.12.80 · Cited by 1
Koh, G. (2014) · The Korean Journal of Obesity · doi:10.7570/kjo.2014.23.1.6 · Cited by 1
Schinner, S. (2009) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(09)79311-4 · Cited by 1
9. Incretin-based Therapy for Type 2 Diabetes Mellitus
Inagaki, N. (2012) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.101.2698 · Cited by 1
Incretin-based therapies for the failing heart
Ussher, J. R., & Campbell, J. E. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000086 · Cited by 1
Метаболічні та психологічні рестрикти корекції харчування дітей із надлишковою масою тіла
Chaychenko, T., & Georgievska, N. (2016) · CHILD`S HEALTH · doi:10.22141/2224-0551.5.1.73.1.2016.78934 · Cited by 1
Саприна, Т. В., Timokhina, Y. S., Мусина, Н. Н., Prokhorenko, T. S., Таширева, Л. А., & Goncharevich, O. K. (2013) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2013-3-132-147 · Cited by 2
Molecular Mechanisms of Alzheimer’s Disease
Bordon, A. (2017) · The Science Journal of the Lander College of Arts and Sciences · Cited by 1
Azegami, T., & Itoh, H. (2019) · Springer eBooks · doi:10.1007/978-981-32-9628-2_4 · Cited by 1
Immunotherapeutic Approach to the Treatment and Prevention of Obesity
Azegami, T., & Itoh, H. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_22 · Cited by 1
Sato, M., Fujita, H., Yokoyama, H., Mikada, A., Horikawa, Y., Takahashi, Y., Yamada, Y., Waki, H., & Narita, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093104 · Cited by 2
“Possible relationships between αGIs such as miglitol and GIP secretion suppression [10–13] and also between the GIP receptor signaling enhancement and fat accumulation [27] have been well appreciated.”
BackgroundSelf-citationOrmoni gastrointestinali e terapia del diabete: dalla fisiologia alle nuove opportunità terapeutiche
Fadini, G. P. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01260-3 · Cited by 2
Differences in GIP Receptor Expression by Feeding Status in the Mouse Brain
Song, D. K., Jung, N., Sung, Y., Hong, Y. S., & Lee, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031142 · Cited by 1
Kruse, M., Keyhani‐Nejad, F., Osterhoff, M. A., & Pfeiffer, A. F. H. (2020) · Peptides · doi:10.1016/j.peptides.2019.170250 · Cited by 1
Kelesidis, T., Kelesidis, I., & Mantzoros, C. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-453-1_3 · Cited by 1
The association of DNA methylation patterns in TCF7L2 and GIPR genes with Type 2 Diabetes
Canivell, S. (2014) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · Cited by 2
Hinke, S. A., Pederson, R. A., & McIntosh, C. H. S. (2006) · Springer eBooks · doi:10.1007/0-387-32824-6_13 · Cited by 1
“Similarly, exendin[9-39] has been employed to demonstrate that GLP-1 is a physiological incretin, and its relative contribution to the”
BackgroundMethod9. Incretin-based Therapy for Type 2 Diabetes Mellitus
Inagaki, N. (2012) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.101.133b · Cited by 1
Renal experiences of bariatric surgery in patients with type 2 diabetes mellitus
Larina, I. M., Severina, A. S., Шамхалова, М. Ш., & Shestakova, M. V. (2018) · Terapevticheskii arkhiv · doi:10.26442/terarkh201890104-108 · Cited by 1
Kheder, M. H. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.122879 · Cited by 1
Müller, W. D. A. (2004) · Springer-Lehrbuch · doi:10.1007/978-3-662-10555-9_11 · Cited by 1
Las hormonas gastrointestinales en el control de la ingesta
Gil‐Lozano, M., Paz, S. F., Pérez, R. B., Federico, V. G. Y., & Férrer, M. T. (2013)
Gastrointestinal Hormones and Obesity
Wang, Y., & Kokkotou, E. G. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1607-5_6
“GIP receptor-deficient mice exhibit a high-fat diet induced obesity resistant phenotype and remain insulin sensitive, suggesting that GIP, or perhaps additional ligands of this receptor, might play an important role in the pathogenesis of obesity [ 66 ].”
BackgroundObesity Insulin Resistance and Gut Hormones
Proietto, J. (2009) · Wiley eBooks · doi:10.1002/9781444307627.ch14
Höfer, M. (2007) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.6712 · Cited by 1
Ramesh, N. (2015) · University Library - University of Saskatchewan (University of Saskatchewan)
Zukunftsperspektiven der medikamentösen Therapie bei Adipositas
Pichler, B., & Ludvik, B. H. (2003) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Barbato, M. T. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2013.tde-10052013-112945
An adipocentric view of the development of insulin resistance
Szalowska, E. (2011) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Role of gastrointestinal hormones in the metabolic dysfunction in obesity and associated diseases
Rudovich, N. N. (2011) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-7245
“The mice seem to have a higher energy expenditure rather than lower energy intake compared with wild-type mice [21].”
BackgroundThe role of gliptins on adipogenesis
Estrada, M. F. (2011) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Glucose-dependent insulinotropic polypeptide – beyond the enteroinsular axis?
Robertson, M. D., Johnston, K. L., & Morgan, L. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000200525.26578.72
Tian, J., Wang, Y., Ning, L. I. N., Zou, D., & Sun, S.-H. (2010) · Academic Journal of Second Military Medical University · doi:10.3724/sp.j.1008.2009.01230
Control del peso corporal. Perspectivas actuales
Gómez‐Ambrosi, J. (2004) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(04)74635-5
Central control of energy homeostasis
DeNino, W. F., Körner, J., & Aronne, L. J. (2003) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200310000-00004
GASTRIC INHIBITORY POLYPEPTIDE IN THE BRAIN
Nyberg, J. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Adolescent type 1 diabetes : Eating and gastrointestinal function
Lodefalk, M. (2009) · DiVA (Digitala Vetenskapliga Arkivet)
Olver, A. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0101080
Genetic Pleiotropies of Obesity
Kahali, B., & Speliotes, E. K. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8642-8_6 · Cited by 1
“Mice with disruption of GIPR are resistant to diet-induced obesity [ 67 ], further supporting a 6 Genetic Pleiotropies of Obesity”
BackgroundNakashima, K., Usami, E., Anbe, E., Yasuda, T., Shibata, T., & Sobajima, H. (2012) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.38.251
Merchant, C. E. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0105089
Rabello, F. R. D. A. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2016.tde-20052016-103421 · Cited by 4
The Role of Incretins in Insulin Secretion
Salehi, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_4-1
Endocrinology of the Gastrointestinal Tract and Modulation of Satiety
Burcelin, R., & Cani, P. D. (2008) · CRC Press eBooks · doi:10.1201/9780849381829.ch11
Pancreatic B -Cell, a Unique Fuel Sensor
Komatsu, M. (2005) · Oxidative stress and disease · doi:10.1201/9781420028362.pt3
Genetic Variants and Risk of Diabetes
Lyssenko, V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801585-8.00020-8
Incretin hormones as a target for therapy
Holst, J. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_2
Self-citationde Cardiologia, P., & Paulo, S. (2016)
Good, D. J. (2008)
Detection of novel obesity loci in Asian populations
Dorajoo, R. (2012) · Spiral (Imperial College London) · doi:10.25560/10142
Carvalho, K. M. M. B. (2015) · Americanae (AECID Library) · Cited by 1
GI Peptides, Energy Balance, and Cancer
Bruno, D. S., & Wolfe, M. M. (2016) · Energy balance and cancer · doi:10.1007/978-3-319-41677-9_11
インスリン分泌研究に魅せられて―臨床から基礎,そして再び臨床へ
暢也, 稲. (2016) · 糖尿病 · doi:10.11213/tonyobyo.59.685
Branham, K. (2015) · SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University)
The Acute Regulation of Intestinal Chylomicron Secretion by Glucagon-like Peptides
Hsieh, J. (2012) · TSpace (University of Toronto)
リリー賞受賞講演 消化管シグナルによる膵β細胞・脂肪細胞の機能連関とその破綻による糖尿病の発症
山田, 祐. (2004) · 糖尿病 · doi:10.11213/tonyobyo1958.47.793
Roles of Gut Hormones in the Regulation of Food Intake and Body Weight
Castagneto‐Gissey, L., Mariolo, J. R. C., & Mingrone, G. (2017) · Endocrinology · doi:10.1007/978-3-319-47685-8_13-1
Fernandes, G. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2017.tde-29112017-091214 · Cited by 1
Do Antibiotics in Early Life Contribute to Obesity
Kadosh, S. (2017) · The Science Journal of the Lander College of Arts and Sciences
Yamaguchi, C., Yamanaka‐Okumura, H., Esumi, H., Masuda, M., Katayama, T., & Taketani, Y. (2018) · The Journal of Medical Investigation · doi:10.2152/jmi.65.203
Generation and use of new tools for the characterisation of gut hormone receptors
Biggs, E. K. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.37487
Effects of Exercise on Incretin Hormones
Toghi-Eshghi, S. R. (2018) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r30g3hd88
Pfeiffer, A. F. H. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/a-0947-2988
“fenbar: GIPR-knock-out-Mäuse werden nicht mehr adipös bei einer Fett- oder Kohlenhydrat-Überfütterung [3, 4].”
BackgroundThe effectiveness of new bariatric surgery in the type 2 diabetes treatment
Grubnik, V. V., Ilyashenko, V. V., Usenok, S. A., Медведев, О. В., & Воротынцева, К. О. (2019) · Surgery of Ukraine · doi:10.30978/su2019-4-21
食後ホルモンインスリン・GLP-1の求心性迷走神経を介した摂食・糖代謝調節
岩﨑, 有., & 俊彦, 矢. (2021) · 自律神経 · doi:10.32272/ans.58.1_105
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Nutritional Approaches and Gastrointestinal Health and Physiology
Saqui–Salces, M. (2014) · University of Minnesota Digital Conservancy (University of Minnesota)
思想的飞刀:是百无一用还是百发百中——读《影响世界历史的100名著排行榜》
孔庆典 (2006) · 民主与科学
Metadata
- Authors
- Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., Hiai, H., Mizunoya, W., Fushiki, T., Holst, J. J., Makino, M., Tashita, A., Kobara, Y., Tsubamoto, Y., Jinnouchi, T., Jomori, T., & Seino, Y.
- Affiliations
- Kyoto University (JP)
- University of Copenhagen (DK)
- Sanwa Kagaku Kenkyusho Co., Ltd. (Japan) (JP)
- Corresponding author
- Seino, Yutaka
- Venue
- Nature Medicine
- Published
- 2002-06-17
- Volume
- 8
- Issue
- 7
- Pages
- 738-742
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2102392334
- Cited by
- 963
- References
- 24
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 64 · 2023: 45 · 2022: 38 · 2021: 39 · 2020: 37 · 2019: 66 · 2018: 39 · 2017: 45 · 2016: 38 · 2015: 42 · 2014: 44 · 2013: 38 · 2012: 38
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, obesity, insulin resistance, high-fat diet, adiposity, respiratory quotient, fat oxidation, anti-obesity drugs, overnutrition
- MeSH terms
- Adipose Tissue, Animals, Body Weight, Crosses, Genetic, Dietary Fats, Gastric Inhibitory Polypeptide, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.